Michael Bober
Clinical Genetics (M.D.) · Wilmington, DENPI 1255422531
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Biomarin Pharmaceutical Inc. accounts for 70.8% of it on its own, with 5 other manufacturers making up the rest.
Across 66 payments — averaging $1107.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$52K
- AstraZeneca$10K
- Ascendis Pharma Endocrinology Inc$7K
- Ultragenyx Pharmaceutical Inc.$2K
- Novo Nordisk$2K
- Pfizer$9
Across 548 payments — averaging $3486.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$1.2M
- Pfizer$218K
- QED Therapeutics, Inc.$204K
- Swedish Orphan Biovitrum AB$114K
- Ultragenyx Pharmaceutical Inc.$54K
- Shire North American Group Inc$37K
- plus $44K from 2 others
What the payments were for
- Consulting fees$25,08134%
- Speaking & faculty fees$30,35542%
- Travel & lodging$12,40817%
- Food & beverage$1,1952%
- Education$4,0386%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 48 | $51,747 |
| AstraZeneca | 11 | $9,725 |
| Ascendis Pharma Endocrinology Inc | 2 | $7,249 |
| Ultragenyx Pharmaceutical Inc. | 2 | $2,308 |
| Novo Nordisk | 1 | $2,040 |
| Pfizer | 2 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few clinical genetics (m.d.) providers in Delawareto place this figure against a meaningful peer group, so we don't.
Other clinical genetics (m.d.) in Wilmington
- Mahim JainWilmington$31K
- Nina Powell-HamiltonWilmington$5K
- Julie KaplanWilmington$393
- Karen GrippWilmington$198
- Bruce BomanNewark$59
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.